Cara Therapeutics, Tvardi Therapeutics enter definitive merger agreement
Written by Emily J. Thompson, Senior Investment Analyst
Merger Announcement: Cara Therapeutics and Tvardi Therapeutics have agreed to merge in an all-stock transaction, with pre-merger stockholders expected to own approximately 17% and 83% of the combined company, respectively. The merger is anticipated to close in the first half of 2025.
Asset Purchase Agreement: Concurrently, Cara will sell certain assets related to Korsuva/Kapruvia to CSL Vifor for $900,000 and will pay an additional $3 million for future expenses, with the asset sale contingent on the successful completion of the merger with Tvardi.
Analyst Views on FMS
Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 22.00 USD with a low forecast of 22.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 21.630
Low
22.00
Averages
22.00
High
22.00
Current: 21.630
Low
22.00
Averages
22.00
High
22.00
About FMS
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
